We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genesis Bioventures Announces Restructuring Management Agreement
News

Genesis Bioventures Announces Restructuring Management Agreement

Genesis Bioventures Announces Restructuring Management Agreement
News

Genesis Bioventures Announces Restructuring Management Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genesis Bioventures Announces Restructuring Management Agreement "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genesis Bioventures, Inc. has announced that it has retained Experigen Management Company to lead its reorganization and restructuring.

Experigen's founder, Douglas C. Lane, an executive with over 30 years experience in pharmaceutical, biotechnology, diagnostics and technology companies, will work closely with GBI's board of directors and officers to develop and execute the plan.

“Mr. Lane's management of business development and mergers and acquisitions at SmithKline Beecham (now GlaxoSmithKline), his interim board experience at Human Genome Sciences, the IPO development at Hyseq Corporation (now Nuvelo) and his recent leadership at the ViaSpace company, ViaLogy Corp., is an excellent fit with our breast cancer diagnostics company and our prion disease rapid assay company,” said Mr. McCartney, Chairman and CEO of Genesis Bioventures.

“We are very pleased to have Mr. Lane lead our growth initiatives.”

“Genesis Bioventures is an undiscovered company with unique growth opportunities,” Mr. Lane said.

“I am looking forward to working with Mr. McCartney, the board and management to create strong value for the Company and its shareholders.”

“There is an outstanding opportunity in GBI and its portfolio companies, with very good science and highly motivated and dedicated management and employees, all prerequisites to success.”

Advertisement